Form 4: Firefly Neuroscience CFO Granted Stock Options and Restricted Stock Units

Paul Krzywicki, CFO of Firefly Neuroscience, received 10,000 restricted stock units and an option to purchase 15,000 shares on March 10, 2025.

Summary

• On March 10, 2025, Paul Krzywicki, the Chief Financial Officer of Firefly Neuroscience, was granted 10,000 restricted stock units (RSUs) under the company's 2024 Long-Term Incentive Plan.
• These RSUs vest quarterly over two years, starting March 10, 2025, and each RSU represents the right to receive one share of common stock.
• Additionally, Krzywicki received an incentive stock option (ISO) to purchase 15,000 shares of common stock at an exercise price of $3.12 per share.
• The ISO vests and becomes exercisable in eight equal quarterly installments over two years from the grant date, with final expiry on 03/10/2035.
• Following these transactions, Krzywicki directly owns 10,000 restricted stock units and has the right to purchase 26,024 shares through incentive stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options and restricted stock units aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The vesting of the restricted stock units and stock options is tied to continued service, incentivizing the CFO to remain with the company.

Industry Context

Granting stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Neurocrine Biosciences and Biogen also utilize stock options and RSUs as part of their executive compensation plans, with vesting schedules typically ranging from two to four years.
• The specific number of shares and exercise price are usually determined based on factors such as the executive's role, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the grant of equity as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the executive team.

Key Dates